Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Stock Buenos Aires S.E.

Equities

BMY

ARDEUT112877

Pharmaceuticals

End-of-day quote Buenos Aires S.E.
Other stock markets
 06:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
19,250 ARS +0.52% Intraday chart for Bristol-Myers Squibb Company +4.33% +16.98%
Jul. 12 UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT
Jul. 11 Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT

Financials

Sales 2024 * 46.07B 42,337B Sales 2025 * 46B 42,270B Capitalization 82.02B 75,373B
Net income 2024 * -5.42B -4,977B Net income 2025 * 10.22B 9,393B EV / Sales 2024 * 2.63 x
Net Debt 2024 * 39.16B 35,989B Net Debt 2025 * 31.88B 29,294B EV / Sales 2025 * 2.48 x
P/E ratio 2024 *
-14.9 x
P/E ratio 2025 *
7.81 x
Employees 34,100
Yield 2024 *
5.95%
Yield 2025 *
6.24%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43 MT
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says MT
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Bristol Myers: accelerated approval in colorectal cancer CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval MT
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43 MT
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day BU
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America AQ
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab AQ
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : approbation accélérée en cancer colorectal
Bristol Myers : demande validée pour Opdivo sous-cutané
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil
Bristol Myers : dividendes décidés par le conseil
Bristol Myers : approbation de la FDA pour un traitement
More news

Quotes and Performance

1 day+0.52%
1 week+4.33%
Current month+2.73%
1 month+4.29%
3 months+13.90%
6 months+4.61%
Current year+16.98%
More quotes

Highs and lows

1 week
18 077.50
Extreme 18077.5
19 475.00
1 month
16 730.00
Extreme 16730
20 083.00
Current year
15 680.00
Extreme 15680
22 442.50
1 year
10 857.50
Extreme 10857.5
22 442.50
3 years
3 635.00
Extreme 3635
22 442.50
5 years
695.33
Extreme 695.3264
22 442.50
10 years
162.43
Extreme 162.4317
22 442.50
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
More insiders

Quotes

Date Price Change Volume
24-07-12 19,250 +0.52% 617
24-07-11 19,150 +0.26% 1,292
24-07-10 19,100 +3.17% 501
24-07-08 18,514 +0.34% 2,118
24-07-05 18,451 -3.14% 2,674

End-of-day quote Buenos Aires S.E., July 11, 2024

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-07-15 - UBS Targeted Protein Degradation Day
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.46 USD
Average target price
52.74 USD
Spread / Average Target
+30.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
PFIZER, INC. Stock Pfizer, Inc.
+0.45% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMY Stock